catalyst · primary record
QTX-2101 + ATRA + IV arsenic trioxide (ATO) + ATRA
Phase readout · 2027-03-01 · Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
| Company | Quetzal Therapeutics |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07504458 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:51.217Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Quetzal Therapeutics:QTX-2101 + ATRA + IV arsenic trioxide (ATO) + ATRA:2027-03-01:P3 primary completion · NCT07504458
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.